Q4 FY26 double-digit volume growth in CDMO
Management expects continued double-digit volume growth in CDMO for Q4 FY26 based on current visibility.
AKUMSDRUGSPHARMACEUTICAL / guidance tracker
Keep management guidance in view.
Akums Drugs & · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
EU CDMO contract annual run-rate of €35 million
The EU CDMO contract is expected to generate annual revenue of €35 million once commercial supplies begin, with supplies starting in FY28.
Zambia project $25 million supplies from H1 FY27
Commercial supplies of $25 million from Indian plants to Zambia expected in H1 FY27, with similar amount in FY28.
Capex to remain in line with historical trend
Capital expenditure for FY27 is expected to be consistent with past levels, focusing on maintenance and modernization.
CDMO double-digit volume growth in H1 FY27
Management expects continued double-digit volume growth in CDMO for the first half of FY27, with visibility of 45-60 days.
Zambia contract to commence by Q2 FY27
Commercial supplies of approximately USD 25 million from Indian facilities to Zambia expected to start by end of Q2 FY27.
Capex target of ₹300 crore for FY27
The company plans to spend around ₹300 crore on capex in FY27, primarily for oral solid capacity expansion.
API losses to reduce sharply in FY27
Management expects API segment losses to come down significantly in FY27, though full-year EBITDA may still be negative.